Heparine Calcique Panpharma

Heparine Calcique Panpharma is a prescription anticoagulant containing heparin calcium. It is supplied for subcutaneous injection; the exact strength and dosage form are not specified in the public data. The product belongs to the antithrombotic class and is marketed within the European Union. It is indicated for prevention and treatment of thromboembolic disorders under medical supervision. The formulation is intended for use by healthcare professionals experienced in anticoagulant therapy.

Heparine Calcique Panpharma is employed in clinical settings to reduce the risk of clot formation in several high‑risk situations.

- Prevention of deep vein thrombosis (DVT) in patients undergoing orthopedic or prolonged immobilization. - Prophylaxis of pulmonary embolism (PE) following major surgery or trauma. - Treatment of established venous thromboembolism, including DVT and PE. - Anticoagulant support during cardiac or vascular surgery to prevent intra‑operative clotting. - Use in patients with a history of recurrent thrombotic events when oral anticoagulants are contraindicated.

Heparine Calcique Panpharma may cause a range of adverse reactions, most of which are related to its anticoagulant activity.

Common: - Minor bruising or bleeding at the injection site. - Small amounts of nosebleed or gum bleeding. - Mild headache. - Transient elevation of liver enzymes.

Serious: - Severe or uncontrolled bleeding, including gastrointestinal or intracranial hemorrhage. - Allergic reactions such as rash, itching, or anaphylaxis. - Thrombocytopenia (low platelet count) potentially leading to bleeding. - Spinal or epidural hematoma after neuraxial procedures.

Before initiating Heparine Calcique Panpharma, clinicians should evaluate patient-specific factors to minimize bleeding risk and ensure safe use.

- Assess baseline coagulation parameters (e.g., aPTT, platelet count) and renal function. - Review history of heparin-induced thrombocytopenia (HIT) or hypersensitivity to heparin. - Adjust dose or avoid use in patients with active bleeding, recent major surgery, or uncontrolled hypertension. - Use caution in pregnant or lactating women; benefits must outweigh potential risks. - Monitor for signs of bleeding or thrombocytopenia during therapy. - Consider dose reduction in elderly or low‑body‑weight patients.

Heparine Calcique Panpharma can interact with other medications that affect hemostasis or share metabolic pathways, requiring careful management.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) unless specifically directed. - Combination with antiplatelet agents such as aspirin, clopidogrel, or NSAIDs in high‑bleeding‑risk patients. - Simultaneous administration of fibrinolytic drugs (e.g., alteplase) without close monitoring.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase gastrointestinal bleeding risk. - Certain antibiotics (e.g., quinolones) that can potentiate anticoagulant effects. - Herbal supplements such as ginkgo biloba, garlic, or high‑dose vitamin E. - Renal impairment that may affect drug clearance.